Skip to main content

Table 8 Summary of the multivariate regression

From: Benefit assessment in Germany: implications for price discounts

Model Summarya
R R2 R2 corr SE
0.404a 0.163 0.076 0.1262671
ANOVAa
  SS df MS F p-value
Regression 0.540 18 0.030 1.882 0.020*
Residual 2.774 174 0.016
Total 3.314 192
Coefficientsa
Predictors (X) Beta SE Coeff (β) p-value
 (constant) 0.228 0.021   0.000
 Major benefit −0.102 0.135 −0.056 0.451
 Considerable benefit −0.033 0.029 −0.091 0.249
 Minor benefit −0.029 0.024 −0.094 0.228
 Non-quantifiable benefit –0.060 0.031 –0.147 0.055
 Less benefit –0.138 0.128 –0.076 0.282
 Diseases of the digestive system 0.061 0.055 0.080 0.270
 Diseases of the genitourinary system –0.002 0.093 –0.001 0.984
 Endocrine, nutritional and metabolic diseases –0.017 0.032 –0.042 0.608
 Other 0.010 0.051 0.016 0.839
 Diseases of the nervous system 0.156 0.047 0.252 0.001**
 Diseases of the musculoskeletal system and connective tissue 0.199 0.129 0.109 0.124
 Certain infectious and parasitic diseases 0.013 0.025 0.043 0.604
 Diseases of the circulatory system 0.043 0.038 0.085 0.264
 Diseases of the skin and subcutaneous tissue 0.199 0.128 0.109 0.122
 Diseases of the blood and blood-forming organs 0.017 0.092 0.013 0.856
 Diseases of the eye and adnexa –0.029 0.052 –0.041 0.575
 Diseases of the respiratory system –0.086 0.046 –0.138 0.064
 Mental and behavioural disorders 0.028 0.092 0.022 0.757
  1. Predictors “Neoplasms” and “No additional benefit” automatically excluded from the model
  2. Abbreviations: Beta standardized coefficient; df degrees of freedom; MS mean squares (SS/dfs); F F statistic; R correlation coefficient; R 2 coefficient of determination; R 2 corr coefficient of determination corrected; SE standard error; SS sums of squares
  3. ** Significant at the 0.01 level
  4. * Significant at the 0.05 level
  5. a Dependent Variable (Y): price change (discount)